



पंचदीप भवन सी॰आई॰जी रोड , नई दिल्ली-110002 PANCHDEEP BHAWAN, C I G MARG, NEW DELHI-110 002 Phone. 011-23604700 Email...dir-gen@esic nic.in Website : www.esic.inc.in / www.esic.in

यू-25/12/Compliance Audit n2023-24/2025-Med.V /149

Dtd:15.04.25

सेवा में,

Deans/Medical Superintendents, PGIMSR's/MC/Hospital Regional Directors, SMO's ESIC DIMS, ESIS All States/UT's

विषय: Recovery of excess payment (if any) from DGESIC approved pharmaceutical firms - reg.

संदर्भ: ESIC Hqrs instructions for Price revision (Downward ONLY) issued for various Central DGESIC Rate Contracts (details enclosed).

महोदया/महोदय,

Reference captioned and in continuation to various instructions issued from ESIC Hqrs for recovery of excess amount (if any) from DGESIC approved pharmaceutical firms for the items where downward revision of rates has been approved and circulated by ESIC HQ.

In this context, it is informed that during performance audit of HQ by Office of the Director General of Audit (Central Expenditure), it has been noticed by Audit that excessive amount from DGESIC approved pharmaceutical firms (for the items where downward revision of rates has been approved and circulated by ESIC HQ) has not been made by various ESI user units.

All ESI Institutions are therefore directed to submit information of the recovery of excess payment (if any) made to the supplier for the amended items (details enclosed) (both in excel and pdf format) to the undersigned latest by 30.04.2025 on the e-mail of dmc-rc@esic.nic.in positively for onward submission to audit.

In case no recovery is pending at your institution end, Nil report may also be sent.

This issues with the approval of Medical Commissioner (Procurement).

Encl: As above

Yours Faithfully Digitally signed by Sanjiv Kochhar Deputy Meglicat 6-0ກາງອອງioner (RC) 15:09:16

Copy to:

1. Medical Commissioner (North -East, South Zone, West Zone, East Zone, North Zone) for information and coordination.

2

ž

- 2. Website Content Manager, Hqrs office for uploading on ESIC website.
- 3. Guard File.

A	В	С	D	E	F	G	н	I	J	К	L	М	N
S. No.	Name of the Firm (M/s.)	Item Name/Brand Name	RC No. Item No.	Existing price in DG ESIC RC	Amedment issuance date	Amended reduced price Effective from	Name of ESIC Hospital/Medical College	Qty Ordered at DGESIC Rate	Amount	Excessive payment made beyond amended price (if any)	Recovery of excess Amount (Y/N)	Pending excessive amount against the firm	Remarks
1	Alpa Laboratories Ltd.	Atropine Inj. Each ml to contain 0.6mg	152 2377	Rs.4.60 per 1ml	09.05.23	Rs. 4.03 per 1ml w.e.f 24.02.23							
2	Reddy's Laboratories Ltd	Rituximab Inj Each Vial contain 100mg	151 1449a	Rs. 1800 per 10ml	22.05.23	Rs. 1646 per 10 ml w.e.f 27.3.23							
3	Reddy's Laboratories Ltd	Oxaliplatin Inj. Each vial contain 50mg	144C 1982	Rs. 2269.52 per 1 vial	14.07.23	Rs. 1987.52 per 1 vial w.e.f 29.5.23							
4	Getwell Pharmaceuticals	Ifosfamide Inj Each vial contain 1gm (FOSFA)	151 457	Rs. 390 per vial	07.08.23	Rs. 315 per vial w.e.f 1.4.23							
5	Johnson & Johnson Private Limited	Golimumab (r-DNA Origin)- Each Single Use Pre- Filled Syringe to contian: Golimumab 50mg/0.5ml	144C 2181	Rs. 39123 per PFS	08.04.24	Rs.19561.50 per PFS w.e.f 23.02.24							
6	Novartis Healthcare Private Limited	Ruxolitinib Tab/Cap- Each Tab/Cap to contains Ruxolitinib 15mg	156 2129	Rs. 2981.20 per Tab/Cap	12.08.24	Rs. 2951.39 w.e.f 30.07.2024							
7	Johnson & Johnson Private Limited	Infliximab Inj- Each Vial to contain: Infliximab 100mg	144C 600	Rs. 15155.58 per vial	23.10.24	Rs. 13500 per vial w.e.f 27.09.24							
8		Ruxolitinib Tab/Cap- Each Tab/Cap Contains Ruxolitinib 5mg	156 2131	Rs. 1487.90 per Tab/Cap	10.12.24	Rs. 1450 per Tab/Cap w.e.f 13.11.24							
9	AstraZeneca Pharma India Limited	Osimertinib Tab/Cap- Each Tab/Cap contain: Osimertinib(as mesylate) 80mg	156 2456	Rs. 277881 per 30 Tabs	23.12.24	Rs. 271315.10 per 30 Tabs w.e.f 26.11.24							